Stoke Therapeutics, Inc. (STOK) Share-based Payment Arrangement, Expense USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Stoke Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2024.
  • Stoke Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $5.41 M, a 8.1% decline year-over-year.
  • Stoke Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $24.8 M, a 4.27% increase year-over-year.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25.3 M, a 10.5% increase from 2022.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $22.9 M, a 38.9% increase from 2021.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $16.5 M, a 185% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $24.8 M $5.41 M -$477 K -8.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $25.3 M $6.06 M +$268 K +4.63% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 $25 M $6.55 M +$626 K +10.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $24.4 M $6.76 M +$597 K +9.69% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $23.8 M $5.89 M +$912 K +18.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $22.9 M $5.79 M +$1.1 M +23.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 $21.8 M $5.93 M +$1.31 M +28.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $20.4 M $6.16 M +$1.71 M +38.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $18.7 M $4.98 M +$2.28 M +84.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $16.5 M $4.69 M +$3.11 M +197% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 $13.3 M $4.61 M +$2.83 M +158% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $10.5 M $4.45 M +$2.8 M +170% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $7.71 M $2.7 M +$1.94 M +258% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $5.77 M $1.58 M +$868 K +122% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 $4.9 M $1.79 M +$1.05 M +144% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $3.85 M $1.65 M +$1.35 M +453% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $2.5 M $754 K +$573 K +317% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $1.92 M $712 K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 $731 K +$691 K +1728% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $298 K +$221 K +287% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $181 K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q3 2018 $40 K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $77 K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.